Walder Wyss advised Alentis Therapeutics on the deal. Honigman advised Catalio Capital Management. Alentis Therapeutics raised $181.4 million in Series D financing, supported by a syndicate...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised CorFlow Therapeutics AG on the deal. Kellerhals Carrard advised Broadview Ventures and Panakes Partners. CorFlow Therapeutics AG completed a series B financing round...
You must be a Standard 1 Year member to access this content.
Bär & Karrer acted as legal advisor to RES in this transaction, Walder Wyss advised Sulzer & Schmid Laboratories AG. RES, a leading independent renewable energy...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Bregal Unternehmerkapital; Bär & Karrer acted for Capvis; Niederer Kraft Frey acted for BSI Software AG. Bregal Unternehmerkapital acquired a majority stake in...
You must be a Standard 1 Year member to access this content.
Walder Wyss has advised ENANTIOS on this transaction. ENANTIOS, an ETH Zurich deep-tech Spin-off, has announced the completion of its seed financing round. The ENANTIOS technology,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised SkyCell AG on all legal and tax aspects of this transaction. SkyCell AG closed its $116 million Series D financing round which embarked...
You must be a Standard 1 Year member to access this content.
Walder Wyss acted as legal counsel to Yasai and its founders; Niederer Kraft Frey advised GreenState AG. Yasai AG and GreenState AG have agreed to merge,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised KLAR Partners on the transaction. KLAR Partners Limited acquired all shares in BÜHLMANN Laboratories AG. BÜHLMANN Laboratories is a Swiss company, located in...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised CRISPR Therapeutics on the issuance. CRISPR Therapeutics AG (NASDAQ: CRSP), a Switzerland-based biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Green Landscaping Group AB (publ) on this transaction. Green Landscaping Group (Publ) continues the expansion journey in Europe and acquires Viva Gartenbau AG,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Nasdaq listed Altamira Therapeutics. Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, entered into a binding...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised SkyCell AG on all legal and tax aspects on this transaction. Swiss based SkyCell AG has completed a USD 57 million equity financing...
You must be a Standard 1 Year member to access this content.
